Arstat Pharmaceuticals is a brand dedicated to improving women's health and enhancing their quality of life. With a strong commitment to addressing prevalent reproductive conditions and disorders, Arstat offers a range of transformational products that are set to revolutionize the industry. Their portfolio includes NUVOCEPT, the first and only contraceptive endorsed by the FDA for exclusive testing and labeling for overweight and obese women.

This groundbreaking product caters to approximately 60% of the 10 million US pill users. Additionally, Arstat presents PREMRING, a first-in-class medicated vaginal ring designed for uterine fibroids and endometriosis, benefiting over 15 million US women. Lastly, they offer ENHANTA, a first-in-class single non-hormonal therapy that aims to alleviate painful and heavy menstrual periods experienced by more than 25 million US women.

With 11 US patents and two phase III-ready products, Arstat's impressive portfolio positions them as a leader in women's health. They are currently seeking partners for a potentially strong IPO, making this an exciting opportunity to be part of their journey. For more information, contact Arkady Rubin, the Chief Scientific Officer and Acting CEO at arubin@arstatinc.

com or visit their website www. arstatinfo. com